BACKGROUND: Dexmedetomidine is a highly selective ␣ 2 -adrenoceptor agonist with sedative, anxiolytic, and analgesic properties that has minimal effects on respiratory drive. Its sedative and hypotensive effects are mediated via central ␣ 2A and imidazoline type 1 receptors while activation of peripheral ␣ 2B -adrenoceptors result in an increase in arterial blood pressure and systemic vascular resistance. In this randomized, prospective, clinical study, we attempted to quantify the short-term hemodynamic effects resulting from a rapid IV bolus administration of dexmedetomidine in pediatric cardiac transplant patients. METHODS: Twelve patients, aged 10 years or younger, weighing Յ40 kg, presenting for routine surveillance of right and left heart cardiac catheterization after cardiac transplantation were enrolled. After an inhaled or IV induction, the tracheas were intubated and anesthesia was maintained with 1 minimum alveolar concentration of isoflurane in room air, fentanyl (1 g/kg), and rocuronium (1 mg/kg). At the completion of the planned cardiac catheterization, 100% oxygen was administered. After recording a set of baseline values that included heart rate (HR), systolic blood pressure, diastolic blood pressure, central venous pressure, systolic pulmonary artery pressure, diastolic pulmonary artery pressure, pulmonary artery wedge pressure, and thermodilution-based cardiac output, a rapid IV dexmedetomidine bolus of either 0.25 or 0.5 g/kg was administered over 5 seconds. The hemodynamic measurements were repeated at 1 minute and 5 minutes. RESULTS: There were 6 patients in each group. Investigation suggested that systolic blood pressure, diastolic blood pressure, systolic pulmonary artery pressure, diastolic pulmonary artery pressure, pulmonary artery wedge pressure, and systemic vascular resistance all increased at 1 minute after rapid IV bolus for both doses and decreased significantly to near baseline for both doses by 5 minutes. The transient increase in pressures was more pronounced in the systemic system than in the pulmonary system. In the systemic system, there was a larger percent increase in the diastolic pressures than the systolic pressures. Cardiac output, central venous pressure, and pulmonary vascular resistance did not change significantly. HR decreased at 1 minute for both doses and was, within the 0.5 g/kg group, the only hemodynamic variable still changed from baseline at the 5-minute time point. CONCLUSION: Rapid IV bolus administration of dexmedetomidine in this small sample of children having undergone heart transplants was clinically well tolerated, although it resulted in a transient but significant increase in systemic and pulmonary pressure and a decrease in HR. In the systemic system, there is a larger percent increase in the diastolic pressures than the systolic pressures and, furthermore, these transient increases in pressures were more pronounced in the systemic system than in the pulmonary system.
D exmedetomidine is a highly selective ␣ 2 -adrenoceptor agonist with sedative, anxiolytic, and analgesic properties. [1] [2] [3] Because it has minimal effects on respiratory drive, dexmedetomidine's use has been reported as part of a balanced anesthetic 4 -6 for the prevention and treatment of emergence delirium, 7 as a primary sedative drug in the intensive care unit, 8 -10 and as a sole drug for sedation during diagnostic procedures such as magnetic resonance imaging 11 and invasive procedures performed in the intensive care unit. 12 The sedative, anxiolytic, and hypotensive effects of dexmedetomidine are mediated via stimulation of central ␣ 2A and imidazoline type 1 (I1) receptors. [13] [14] [15] [16] The activation of these central receptors results in a decreased catecholamine release and an overall reduction in the sympathetic outflow from the locus ceruleus of the brainstem. The analgesic effects of dexmedetomidine are thought to be the result of activation of ␣ 2B -adrenoceptors at the level of the dorsal horn of the spinal cord and the inhibition of substance P release. Dexmedetomidine's peripheral vascular effects result from stimulation of ␣ 2Badrenoceptor in the peripheral vasculature and cause an initial increase in systemic vascular resistance (SVR) and decrease in the cardiac output (CO). 15, 17 The hemodynamic effects of a slow bolus administration of dexmedetomidine over 10 minutes has been well described with regard to heart rate (HR) and arterial blood pressure in children. 18 -21 In these studies, dexmedetomidine administration resulted in a decrease in blood pressure and HR. In adults, dexmedetomidine has been administered over 2 minutes, resulting in a biphasic hemodynamic response with an initial increase in blood pressure and reflex bradycardia followed by a stabilization of blood pressure and HR below baseline values. 22, 23 However, there are no data in the pediatric or adult literature concerning the hemodynamic effects after a rapid bolus.
Dexmedetomidine is used frequently to prevent and treat postoperative agitation 7,24 -26 in doses of 0.25 to 1 g/kg. Whereas preemptive administration is ideal in the prevention of postoperative agitation, a child who emerges from anesthesia with acute delirium requires prompt treatment because they can pose a significant risk to themselves and those around them. The use of dexmedetomidine as an infusion over 10 minutes in such a situation is impractical and although in the above studies dexmedetomidine was administered over 2 to 5 minutes, it is now common practice at our institution to administer dexmedetomidine as a rapid (Ͻ5 seconds) IV bolus. We therefore designed a descriptive study in pediatric heart transplant patients to invasively measure systemic and pulmonary hemodynamics as well as CO during cardiac catheterization.
METHODS
The study was approved by the IRB of the University of Pittsburgh and parental informed consent was obtained before the procedure. All patients were undergoing routine surveillance cardiac catheterization and endomyocardial biopsies as a part of their post-heart transplant medical management. All patients 10 years of age or younger and weighing Յ40 kg were eligible for enrollment. Patients were excluded if they had received dexmedetomidine in the preceding week or had an allergy to dexmedetomidine. Patients were allowed clear fluids up to 2 hours before surgery and received IV or oral premedication of midazolam as needed. After standard ASA monitors were placed, induction of general anesthesia was achieved either by inhaled (sevoflurane, 40% oxygen, 60% nitrous oxide) or IV (propofol, 100% oxygen) methods. After induction, tracheal intubation was facilitated with rocuronium (1 mg/kg). Anesthesia was maintained with approximately 1 minimum alveolar concentration of isoflurane in room air, and fentanyl (1 g/kg) was administered just before the arterial and venous catheter (internal jugular vein and femoral artery) insertions. At the completion of the planned cardiac catheterization (approximately 1 hour after induction of anesthesia), and with the end-tidal isoflurane concentration of 1.2 and the fraction of inspired oxygen at 1.0, baseline values of HR, systolic blood pressure (SBP), diastolic blood pressure (DBP), central venous pressure (CVP), systolic pulmonary artery pressure, diastolic pulmonary artery pressure, pulmonary artery wedge pressure (wPAP), and 3 thermodilution COs were recorded using indwelling catheters. The SVR and pulmonary vascular resistance (PVR) were calculated from these values. After these baseline measurements, a rapid IV bolus dose of either 0.25 or 0.5 g/kg dexmedetomidine was administered over 5 seconds. The dose administered to each patient was determined by alternating the dose to sequentially enrolled patients, i.e., the first patient enrolled received 0.25 g/kg, the second patient received 0.5 g/kg, the third 0.25 g/kg, etc. We successfully enrolled every available patient. The HR and systolic and pulmonary blood pressures were recorded continuously but only their 1-and 5-minute values were recorded for analysis whereas the wPAP and CO measurements were taken only at the 1-minute (peak effect) and at the 5-minute time points after the IV administration of dexmedetomidine. The 5-minute time point was chosen from preliminary studies that showed that all arterial blood pressure measurements had returned to baseline by this time. Because the hemodynamic effects were so transient, only 1 thermodilution CO was done at the 1-minute time point. All measurements were taken using the indwelling catheters and recorded on the Philips Witt Hemodynamic System (Philips Corporation, Melbourne, FL). At the end of the procedure, the groin catheters were removed and the patient was awakened and admitted to the postanesthesia care unit for recovery.
Statistical analysis was performed using SPSS 16.0 for Windows (SPSS Inc., Chicago, IL). Values are presented as mean Ϯ SD. For demographic data, a t test was used with a P value Յ0.05 indicating significance. For physiologic data, the graphs are presented with independent variables of either time (time 0, 1 minute, and 5 minutes after intervention) or dose (0.25 g/kg and 0.5 g/kg). Because this study was purely descriptive, no other statistical tests were performed, and the complete dataset for each patient is presented in the Results section.
RESULTS
Twelve children were enrolled in the study. Six received 0.25 g/kg and 6 received 0.5 g/kg dexmedetomidine. No significant differences were found in baseline demographic characteristics between the 2 dosage groups (Table 1). The average values of the hemodynamic variables as functions of both dose and time are presented in Table 2 .
In every child, SBP and DBP increased at 1 minute and then decreased to approximately the baseline value at 5 minutes for both the 0.25 g/kg ( Fig. 1 ) and the 0.5 g/kg (Fig. 2 ) doses, although it was nearly imperceptible in subject 12 (0.25 g/kg). There was less change in pulmonary arterial pressures; although in those children in whom there was any appreciable change (e.g., subject 2), the small increase at 1 minute was transient and not observed at 5 minutes. There was a transient increase in wPAP at 1 minute, which returned to baseline at 5 minutes (Figs. 3 and 4 for the 0.25 and 0.5 g/kg doses, respectively). There was no clear pattern to the very modest changes in CVP and CO ( Figs. 3 and 4 ), and none of the changes were of clinical concern.
Table 3 shows the percent change from baseline at 1 and 5 minutes for the various hemodynamic variables measured. Consistent with the graphs, the hemodynamic changes were transient and did not appear to be of any clinical concern. However, the percent increase in DBP appeared to be larger than the percent increase in SBP for both doses and, furthermore, the percent increase in DBP was larger than the percent increase in diastolic pulmonary artery pressure for both doses at the 1-minute time point. HR was the only hemodynamic variable for which visual inspection of the data suggested a different pattern of response for the 0.25 and 0.5 g/kg doses. One minute after the bolus, HR decreased in every child except for subject 6, who was inexplicably bradycardic at baseline. The HR response at 1 minute was indistinguishable between the 2 groups ( Fig. 5 and Table 3 ). However, at 5 minutes, the HR in children receiving 0.25 g/kg returned toward baseline, except for subject 6, in whom the baseline bradycardia simply appeared to be resolving. A different pattern was seen in subjects receiving 0.5 g/kg. In these children, there was further slowing of the HR 5 minutes after the dose.
SVR followed the same pattern as arterial blood pressure. In every child, SVR increased above baseline at 1 minute and returned to approximately the baseline value at 5 minutes ( Fig. 6 ). PVR, with the exception of 1 patient in each group, did not show an overall change from baseline ( Fig. 7) at any time point or dose.
The pulmonary to systemic blood pressure ratios were investigated as described by Lazol et al. 27 and were not different from baseline in either of the 2 groups at any of the time points (Table 4 ).
DISCUSSION
The rapid bolus administration of dexmedetomidine results in a transient but significant increase in systemic and pulmonary pressure. All hemodynamic measurements, except for the HR in the 0.5 g/kg group, returned to baseline by 5 minutes. In the systemic circulation, diastolic pressures increase more than systolic pressures and the increase in pressures and resistance are greater in the systemic circulation than in the pulmonary system. Dexmedetomidine, a highly selective ␣ 2 -adrenergic agonist, has both sedative and analgesic properties. Currently, dexmedetomidine has Food and Drug Administration approval for use in intensive care unit sedation and procedural sedation in adult populations. Despite this relatively limited Food and Drug Administration approval, dexmedetomidine has been used widely and with relatively few adverse reactions in pediatric anesthesia and critical care medicine. Although infusions of the drug have been well reported, the acute hemodynamic effects after a rapid bolus administration have not been described. At our institution, rapid IV bolus administration occurs frequently when treating emergence delirium in children. The post-heart transplant pediatric patient undergoing routine surveillance cardiac catheterization provided a unique opportunity to be able to invasively measure CO and both systemic and pulmonary pressures and resistances both before and after IV bolus dexmedetomidine administration.
In both human and animal models, dexmedetomidine produces a biphasic blood pressure effect: an initial but transient increase in blood pressure followed by a longlasting hypotensive effect. 23, 28 The initial increase in SBP is thought to be from vasoconstriction secondary to stimulation of peripheral postsynaptic ␣ 2B -adrenergic receptors in the vascular smooth muscle. The longlasting stabilization of blood pressure and HR at values slightly below the baseline is most likely the result of activation of central presynaptic ␣ 2A -adrenergic receptors resulting in sympatholysis.
In a study by Ebert et al., 22 10 healthy volunteers were subject to increasing concentrations of a dexmedetomidine infusion. Initially, at the low infusion rates, the classic decrease in blood pressure and HR was documented; however, as the infusions increased to supraclinical doses, Ebert et al. observed significant incremental increases in the systemic and pulmonary pressures, SVR, PVR, wPAP, and CVP. The initial increases in systemic blood pressure, pulmonary blood pressures, SVR, and PVR were most likely caused by peripheral vasoconstriction resulting from stimulation of postsynaptic ␣ 2B -adrenergic receptors in the vascular smooth muscle. 29 -32 From our data, it seems that DBP is affected more than SBP (30%-50% vs 20%-30%, respectively) in post-cardiac transplant patients and that these transient increases in pressures and vascular resistances are greater in the systemic system than in the pulmonary system. Although there are theoretical concerns regarding the safety of dexmedetomidine use in patients with pulmonary hypertension, 22, 29, 33 the pulmonary to systemic blood pressure ratio (often used to describe the severity of pulmonary hypertension, with pulmonary pressures approximately 20%-25% of the systemic pressure being normal) suggests that dexmedetomidine has less of an effect on PVR than on SVR ( Table 4 ). The apparent plateau effect observed in the pulmonary vasculature suggests that the density of ␣ 2B -adrenergic receptors in the pulmonary bed may be reduced compared with the systemic vasculature, or the increase in pulmonary pressure reflects the increase in systemic blood pressure rather than receptor-mediated vasoconstriction.
It should be noted that in our patient population with their denervated transplanted hearts, the loss of reflex control of HR may actually enhance the increased blood pressure effects of vasoconstrictive agents, such as norepinephrine, or in this case dexmedetomidine. 34 Therefore, the increases in blood pressures resulting from the rapid IV bolus administration of dexmedetomidine might be somewhat mitigated in patients with an intact autonomic reflex.
There are ␣ 2 -adrenergic and imidazoline I1 receptors in human heart tissue. 35, 36 Whereas the central effects on these receptors are known, the effects that dexmedetomidine might have on these myocardial receptors is unclear. Flacke et al. 37 showed in an isolated dog heart model that pharmacologic doses of dexmedetomidine resulted in a direct release of catecholamines from cardiac stores. This phenomenon may occur with rapid IV bolus administration, which might account for the increase in blood pressure, SVR, and PVR.
In our study, the acute decrease in HR after dexmedetomidine administration in the transplant patient with a denervated heart was unexpected. In denervated dog model experiments by Flacke et al., 37, 38 no changes in HR after the administration of dexmedetomidine were reported. Xu et al., 30 using a rabbit model, defined the role of the autonomic nervous system in the hemodynamic effects of dexmedetomidine. They concluded that the initial HR decrease after a dexmedetomidine bolus is the result of activation of the baroreceptor reflex and that the sustained HR decrease is mediated via the central sympathetic depression, i.e., inhibition of the sympathetic and activation of the parasympathetic nervous system. The role of the myocardial ␣ 2 -adrenergic and imidazoline I1 receptors is unclear as one would expect the HR to increase if the stimulation of these myocardial receptors resulted in a direct release of catecholamines from cardiac stores. Hammer et al. 39 studied healthy children undergoing radiofrequency ablation for supraventricular tachycardia using propofol and ketamine as their anesthetic. Although none of the patients in the study by Hammer et al. developed clinically significant bradycardia, dexmedetomidine significantly depressed sinus and atrioventricular nodal function. Our findings of a sustained decrease in HR in these patients with denervated hearts suggest that further investigation is needed to clarify the potential direct interaction of dexmedetomidine on sinus node activity. A limitation of our study is our small sample size; larger patient numbers may have shown a dose effect, particularly in the systemic circulation, and would have allowed statistical testing. Nonetheless, we believe that these data provide the background for a proper power analysis and large-scale study. Because of the very transient nature of these hemodynamic changes, a further potential limitation was the use of a thermodilution CO measurement technique instead of a continuous technique, which limited us to 1 CO measurement at the 1-minute time interval. A further possible limitation of the study might be that no data were recorded while the subjects' lungs were being ventilated with room air and the pulmonary vasodilator effect of 100% oxygen may have influenced the results.
This rapid bolus administration method of dexmedetomidine should not be extrapolated to either adults or healthy children because there have been reports of significant hypotension, bradycardia, and sinus arrests with its administration. 1, 5, 40, 41 It should be further noted that there have been case reports of significant bradycardia in pediatric patients with congenital heart disease and on cardiac medication such as digoxin. 42 It may be that children with their relatively more rapid HRs, decreased incidence of sinus node dysfunction, and decreased use of HRdecreasing medications such as ␤-blockers and digoxin allow for more liberal use of dexmedetomidine.
In conclusion, the rapid IV bolus administration of 0.25 and 0.5 g/kg dexmedetomidine in this small sample of children having undergone heart transplants was clinically well tolerated, although it resulted in a transient but significant increase in systemic and pulmonary pressure and a decrease in HR. In the systemic system, there is a larger percent increase in the diastolic pressures than the systolic pressures and, furthermore, these transient increases in pressures were more pronounced in the systemic system than in the pulmonary system.
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